These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 36002104)
1. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts. Holmberg LA; Linenberger M; Connelly-Smith L Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104 [TBL] [Abstract][Full Text] [Related]
2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
3. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era. Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641 [TBL] [Abstract][Full Text] [Related]
4. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
5. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982 [TBL] [Abstract][Full Text] [Related]
6. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach. Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941 [TBL] [Abstract][Full Text] [Related]
7. Hematopoietic Progenitor Cell Counts of the Leukapheresis Product Determined Using Sysmex XN Analyzers Predict a Sufficient Number of CD34 Imoto N; Kondo Y; Uchida K; Kurahashi S Intern Med; 2024 Jan; 63(2):189-195. PubMed ID: 37225486 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490 [TBL] [Abstract][Full Text] [Related]
9. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037 [TBL] [Abstract][Full Text] [Related]
10. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892 [TBL] [Abstract][Full Text] [Related]
11. Impact of mobilization regimen on multiday collection of peripheral blood CD34+ cells by large volume leukapheresis. Siddiqui I; Shmookler A; Biller E; Hardy T; Hartage R; Losos M; Chen J Transfusion; 2022 Apr; 62(4):857-862. PubMed ID: 35211978 [TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience. Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769 [TBL] [Abstract][Full Text] [Related]
14. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458 [TBL] [Abstract][Full Text] [Related]
15. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180 [TBL] [Abstract][Full Text] [Related]
17. G-CSF + plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Li Y; Qiu X; Lei Y; Zhou R Ann Med; 2024 Dec; 56(1):2329140. PubMed ID: 38470973 [TBL] [Abstract][Full Text] [Related]
18. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation]. Chen J; Yuan LL; Zhang X; Qiao JL; Yin QX; Zhang YM; Yang XL; Cao XY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):286-291. PubMed ID: 35123641 [TBL] [Abstract][Full Text] [Related]
19. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization. Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]